Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $155 million, with $138 million excluding license and royalty revenue, down 2% year over year [5][20] - Total consumables revenue was $115.4 million, up 5%, while instrument revenue was $14.8 million, down 42% [20][21] - Gross profit for Q1 was $105.4 million, with gross margins increasing to 68% from 66% year over year [22] Business Line Data and Key Metrics Changes - Chromium consumables revenue was approximately flat at $84.1 million, while spatial consumables revenue increased by 18% to $31.2 million, driven by Xenium consumables [20][21] - Total instrument revenue saw a significant decline, with Chromium instrument revenue down 25% and spatial instrument revenue down 49% [21] Market Data and Key Metrics Changes - Revenue in the Americas decreased by 7% to $73.8 million, EMEA decreased by 8% to $31.9 million, while APAC increased by 22% to $32.4 million [22] - Instrument revenue declined across all geographies, although strong consumable sales helped offset the impact in APAC [22] Company Strategy and Development Direction - The company is navigating a challenging macro environment, withdrawing full-year revenue guidance and implementing quarterly guidance due to uncertainty in U.S. academic and government research funding [10][25] - A focus on cost-saving measures, including an 8% reduction in workforce, is aimed at maintaining a strong balance sheet while continuing to invest in key priorities [12][29] - The company is committed to long-term growth, with confidence in capturing large opportunities despite current challenges [19][30] Management's Comments on Operating Environment and Future Outlook - Management highlighted a deteriorating research funding environment, with significant impacts on customer purchasing behavior and project initiation [9][10] - There is optimism regarding the long-term potential of the company's products, particularly in single-cell and spatial biology, despite current market challenges [11][19] - The company is closely monitoring the evolving tariff landscape, with minimal reliance on China in its supply chain [27][28] Other Important Information - The company has completed a sales reorganization to enhance focus and coverage in the current environment [11] - Recent product launches have been well-received, contributing to increased usage and adoption among customers [14][15] Q&A Session Summary Question: Current backdrop and customer conversations - Management noted that customer conversations have become increasingly dire due to funding uncertainties, prompting cost-cutting measures among institutions [42][44] Question: Year outlook and instrumentation vs consumables - Management indicated that Q2 is expected to mirror Q1 trends, with pressure on CapEx in instrumentation but stable consumables performance [55][56] Question: Headcount reduction and OpEx initiatives - The company emphasized that the headcount reduction will lead to over $50 million in operating expense savings for 2025, while still retaining critical talent for growth [70][69] Question: Regional sales dynamics - Management acknowledged that while EMEA sales have declined, the fundamental business remains strong, and recent hiring in Europe is expected to improve performance [76][75] Question: Demand in APAC and potential pull forward - Strong underlying demand in APAC, particularly in China and Japan, was noted, with structural improvements contributing to robust performance [78][79] Question: Long-term growth opportunities in organoid research - Management expressed optimism about the potential for single-cell sequencing in organoid research, viewing it as a promising growth area [99][98] Question: Tariffs and demand in China - The company does not anticipate significant pull forward in demand due to tariffs, and it has strategies in place to mitigate potential impacts [108][107]

PSQ Holdings (PSQH) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 you for standing by. My name is Gail, and I will be the operator for today's call. At this time, I would like to welcome each and every one of you to the Public Square First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer It is now my pleasure to turn today's call over to William Penn. Please go a ...

PubMatic (PUBM) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, everyone, and welcome to Palmatic's earnings call for the first quarter twenty twenty five. This is Stacy Clements with the Blueshirt Group, and I'll be your operator today. Joining me on the call are Rajeev Goel, cofounder and CEO and Steve Pantalek, CFO. Before we get started, I have a few housekeeping items. Today's prepared remarks have been recorded, after which Rajeev and Steve will host live q and a. If you plan t ...

DoubleVerify (DV) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Greetings, and welcome to the DoubleVerify First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Tijo Ingeman, Senior Vice President of Investor Relations. Thank you. You may begin. Speaker1 Good afterno ...

GrowGeneration (GRWG) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Hello, everyone, and welcome to GrowGeneration's First Quarter twenty twenty five Earnings Conference Call. My name is Joelle, and I will be your conference operator for today's call. At this time, participants are in a listen only mode. Following prepared remarks, we will open the call to questions from analysts with instructions to be given at that time. This conference call is being recorded and a replay of today's call will be ...

ZimVie (ZIMV) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to ZIMVY's First Quarter twenty twenty five Earnings Conference Call. Currently, all participants are in a listen only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Webb Campbell from Gilmartin Group for today's introductory disclosures. Speaker1 Thank you all ...

Financial Data and Key Metrics Changes - Revenue for Q2 increased to $181.7 million, a 62.5% increase year-over-year and a 12% increase quarter-over-quarter [25][26] - Gross profit reached nearly $100 million, up 5% sequentially and more than 24% year-over-year, with a gross margin of 53% [4][26] - The company reported a net loss of $138.8 million, primarily due to a decline in Bitcoin spot prices [27][12] - Adjusted EBITDA was a negative $57.8 million, but operations produced approximately $70 million of positive EBITDA when normalized [27][28] - The marginal cost per Bitcoin rose to approximately $42,600, a 26% increase over the previous quarter [28] Business Line Data and Key Metrics Changes - Bitcoin production for the quarter was 19.57 Bitcoin, a slight decrease of 3.6% year-over-year despite a halving event [25][26] - Average revenue per Bitcoin produced was $92,811, an increase of 69% year-over-year [26] - Cash overhead decreased by 16% quarter-over-quarter [10] Market Data and Key Metrics Changes - Bitcoin traded at approximately $81,000 at quarter-end, down from $93,000 at the start of the year [12] - The company’s Bitcoin treasury now exceeds 12,101 Bitcoin, valued at over $1.2 billion at current prices [31][11] Company Strategy and Development Direction - The company is transitioning from a nearly 100% HODL strategy to using a portion of monthly Bitcoin production to support operations [8][31] - CleanSpark aims to reach 50 exahash by mid-2025 and has plans for further expansion beyond that [10][19] - The company is focused on maintaining a strong balance sheet and avoiding equity dilution, contrasting with peers who rely on such methods [8][32] Management's Comments on Operating Environment and Future Outlook - Management highlighted resilience amid rising energy prices, declining Bitcoin prices, and increasing mining difficulty [12][21] - The company is well-positioned to capitalize on market opportunities, particularly in acquiring smaller miners at attractive valuations due to tariff pressures [15][69] - Management emphasized a disciplined approach to capital management and strategic flexibility in a volatile market environment [19][32] Other Important Information - CleanSpark was ranked number 35 in the Financial Times 2025 list of the 500 fastest-growing companies in the Americas [20] - Institutional ownership in the company increased to nearly 64% following its inclusion in the S&P SmallCap 600 Index [20] Q&A Session Summary Question: Outlook for network cash rate growth in 2025 and CleanSpark's market share - Management noted a plateau effect in network growth but believes CleanSpark is well-positioned to maintain and grow its market share, currently at about 5% [42][43] Question: How the digital asset management team will generate shareholder value - The team is focused on selecting the right partners and utilizing strategies like covered calls to generate cash flow and maintain flexibility [44][45] Question: Impact of competitors pivoting to HPC on mining rig pricing - Management indicated that reduced demand from larger players has created opportunities for CleanSpark to acquire rigs at lower costs, with expectations of continued price decreases [51][54] Question: Coverage of CapEx through Bitcoin sales - Management clarified that monthly operational expenses are around $35 million, and excess revenue from Bitcoin sales can be allocated towards CapEx or debt servicing [55][58] Question: Consideration of using Bitcoin holdings to repurchase shares - Management is open to various capital strategies but prioritizes growing the Bitcoin balance and enhancing shareholder value through operational investments [62][65] Question: Future of Bitcoin-backed facilities and market for acquisitions - Management expressed interest in bolt-on acquisitions, especially if valuations are favorable, and noted that they are always open to opportunities in the market [68][69]

Financial Data and Key Metrics Changes - Revenue increased to $4.2 million in Q1 2025 from $3.8 million in Q1 2024, primarily due to higher milestone revenue from GenmAb's clinical program [24] - Operating expenses decreased to $23 million from $26.4 million year-over-year, with R&D expenses down to $12.6 million from $14.6 million [25] - Net loss for Q1 2025 was $18.2 million or $0.17 per share, compared to a net loss of $19 million or $0.19 per share in Q1 2024 [26] Business Line Data and Key Metrics Changes - The number of active partners grew to 95, with new deals signed with Harvard's Weiss Institute, Takis Biotech, and Orion Corporation [8] - Total active programs increased to 378, with 33 active clinical programs and approved products as of the end of Q1 [10] Market Data and Key Metrics Changes - The company expects to receive a $3 million upfront payment from Angelini Pharma, with potential milestones exceeding $170 million [9] - The portfolio of post-discovery stage assets has increased by over 39% in the last two years [11] Company Strategy and Development Direction - The launch of the exploration partner access program aims to enhance partner workflows and create new revenue streams [14][21] - The company remains focused on licensing novel discovery technology to the pharmaceutical industry, which is the foundation of its strategy [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong deal flow and the robustness of new partnerships despite broader industry challenges [5] - The company anticipates that the exploration program will be accretive to earnings and cash flow in both the short and long term [23] Other Important Information - The company implemented a reduction in force in early February, resulting in an additional cash outlay of approximately $1 million in Q1 [27] - Guidance for 2025 revenue remains between $20 million and $25 million, excluding contributions from the exploration program [28] Q&A Session Summary Question: What attributed to the strong number of program starts this quarter? - Management noted that continued innovation and the launch of new technologies have driven interest from both new and existing partners [30][31] Question: Is the exploration platform exclusively for existing partners? - Yes, the exploration partner access program is available only to partners within the OmniAb ecosystem [35] Question: Can you provide any benchmarks for potential partners for the exploration program? - Management indicated that while it is difficult to provide exact numbers, they have deep relationships with partners and are targeting those most likely to benefit from the exploration instruments [42] Question: What are the key differentiators of the exploration platform? - Key differentiators include ease of use, high efficiency, and the absence of fluidics, which reduces maintenance issues [48] Question: How do tariffs impact the business? - Management stated that there are minimal impacts from tariffs as the exploration instrument and most parts are manufactured in the U.S. [51] Question: Will new partners also have access to the exploration platform? - Yes, new partners will have access to the exploration platform as they sign up [58]

Corvus Pharmaceuticals (CRVS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, everyone. Thank you for standing by, and welcome to the Carvus Pharmaceuticals first quarter twenty twenty five business update and financial results conference call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. It is now my pleasure to turn the call over to Zach Kubo of Real Chemistry. Please go ah ...

Lisata Therapeutics (LSTA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Welcome to the Losada Therapeutics First Quarter twenty twenty five Financial Results and Business Update Conference Call. Currently, participants are in listen only mode. Following management's prepared remarks, we will hold a Q and A session. As a reminder, this call is being recorded today, Thursday, 05/08/2025. I will now turn the call over to John Mendito, Vice President of Investor Relations and Corporate Communications ...